Recruiting

NC Testing

Sponsor:

University of Calgary

Code:

NCT05914649

Conditions

Postural Orthostatic Tachycardia Syndrome

Post Acute Sequelae of SARS CoV 2 Infection

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

IV normal saline (999 mL infusion)

IV normal saline (50 mL infusion)

Study Details

Brief summary:

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).

Conditions

Postural Orthostatic Tachycardia Syndrome

Post Acute Sequelae of SARS CoV 2 Infection

Study ID

NCT05914649

Start date

Sep 19, 2024

Status verified date

Apr, 2026

Completion date

Dec 31, 2030

Anticipated

Primary completion date

Dec 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Patients with diagnosis of Long COVID
  • SARS-COV2 test positive
  • Symptoms > 12 weeks post COVID
  • Subjective complaint of 'brain fog" or cognitive dysfunction
  • Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic
  • Subjective complaint of 'brain fog" or cognitive impairment
  • Healthy participants
  • Without POTS or "brain fog"
  • Age 18 to 60 years
  • Female and Male
  • Able to give an informed consent

Exclusion Criteria:

  • Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest)
  • An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.
  • Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.
  • Unable to give an informed consent.

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: 999 mL normal Saline

999 mL of normal saline infused intravenously.

placebo comparator: 50 mL normal Saline

50 mL of normal saline infused intravenously.

Interventions

IV normal saline (999 mL infusion)

999 mL of IV normal saline will be infused intravenously

IV normal saline (50 mL infusion)

50 mL of IV normal saline will be infused intravenously as a placebo control.

Primary outcome measure

  • 5RTI Reaction Time task (Standing) [ Time Frame: During Procedure (3 hours) ]

Central Contacts and Locations

Central contacts

Satish R Raj, MD MSCI

(403)210-6152autonomic.research@ucalgary.ca

Rasha Hamzeh, RN

autonomic.research@ucalgary.ca

Locations

University of Calgary

Recruiting

Calgary, Alberta, Canada, T2N 4Z6

Contacts

Satish R Raj, MD, MSCI

403-210-6152autonomic.research@ucalgary.ca

Robert S Sheldon, MD, PhD

403-220-8191autonomic.research@ucalgary.ca

More Information

Sponsor

University of Calgary

Last update posted

May 7, 2026

Last verified

Apr, 2026

Keywords

  • POTS
  • Long COVID
  • Cognitive
  • Brain Fog

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Calgary on 2026-05-07.